Keros Therapeutics, Inc. KROS R2KR3KPHARMA
Company Overview
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Why Investors Should Care
Return on capital employed stands at 21.3%.
Revenue has grown at a 70.3% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Dec 2025 Revenue of $244.06M (+6775.0% YoY); net profit $87.01M.
- 5-Year Trend Long-term compounding — revenue CAGR 70.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 70.31% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -18.91% |
| 6 Months: | +0.18% |
| 3 Months: | +9.90% |
| 1 Month: | +6.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)55.90 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 21.3%.
- Compounding revenue at 70.3% over 5 years.
CONS
- Trading 48.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KROS Keros Therapeutics, Inc. R2KR3KPHARMA | 11.32 | -3.52 | $224.44M | 0.00% | 21.27% | -17.16% | 70.31% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.50M | 2.50M | 2.50M | 0 | 0 | 0 | - | 100.00K | 0 | - | 0 | 0 | 0 | 0 | 8.00K | 83.00K | 37.00K | 388.00K | 211.25M | 18.17M | 14.26M | 385.00K | 367.00K | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 59.21M | 57.98M | 29.65M | 29.66M | 26.24M | - |
| Operating Income | -2.86M | -2.65M | -2.33M | -10.50M | -10.91M | -11.95M | -15.77M | -15.54M | -20.20M | -24.13M | -30.73M | -27.98M | -38.87M | -41.34M | -43.28M | -48.48M | -50.44M | -58.66M | 152.04M | -39.82M | -15.38M | -29.27M | -25.88M | -30.94M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 152.38M | -39.45M | -14.99M | -28.87M | -25.47M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 158.49M | -32.92M | -8.70M | -24.98M | -23.71M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.04M | -2.22M | -1.42M | -1.51M | 0 | - |
| Net Income | -3.18M | -2.85M | -3.55M | -11.89M | -10.76M | -12.04M | -15.88M | -15.62M | -20.30M | -24.19M | -27.27M | -23.51M | -35.80M | -37.51M | -39.44M | -43.11M | -45.26M | -52.96M | 148.45M | -30.70M | -7.28M | -23.46M | -23.71M | -28.71M |
| Diluted EPS | - | - | - | - | -0.62 | -0.60 | -0.68 | -0.67 | -0.87 | -1.01 | -1.13 | -0.92 | -1.26 | -1.27 | -1.33 | -1.21 | -1.25 | -1.41 | 3.62 | -0.76 | -0.18 | -0.86 | -1.21 | -1.45 |
| R&D Expense | 4.87M | 4.50M | 3.85M | 8.53M | 7.26M | 8.39M | 11.49M | 9.98M | 14.83M | 18.08M | 23.28M | 21.04M | 31.09M | 32.53M | 34.14M | 38.26M | 40.52M | 49.23M | 48.71M | 43.50M | 19.52M | - | 16.10M | 22.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 10.00M | 0 | 20.10M | 0 | 151.00K | 3.55M | 244.06M |
| Operating Income | -10.56M | -46.66M | -56.37M | -114.79M | -169.94M | -210.83M | 67.57M |
| Net Income | -12.34M | -45.36M | -58.74M | -104.68M | -152.99M | -187.35M | 87.01M |
| Diluted EPS | - | -2.93 | -2.52 | -4.15 | -5.20 | -5.00 | 2.30 |
| R&D Expense | 17.38M | 33.86M | 55.14M | 87.27M | 135.26M | 173.63M | 129.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 10.96M | 269.44M | 255.25M | 306.78M | 370.02M | 615.89M | 338.02M |
| Total Equity | -7.18M | -19.45M | 261.72M | 243.17M | 277.42M | 332.21M | 571.55M | 303.13M |
| Cash & Equivalents | - | 7.02M | 265.88M | 230.04M | 279.05M | 331.15M | 559.93M | 287.42M |
| Total Liabilities | - | 10.46M | 7.72M | 12.08M | 29.36M | 37.81M | 44.33M | 34.89M |
| Current Liabilities | - | 4.49M | 7.18M | 11.85M | 16.55M | 24.37M | 27.45M | 20.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.00M | -36.89M | -62.15M | -70.06M | -124.51M | -160.87M | 107.50M |
| Investing Cash Flow | -271.00K | -294.00K | -1.02M | -1.24M | -2.46M | -1.93M | -1.55M |
| Financing Cash Flow | 14.00K | 296.04M | 28.55M | 120.31M | 178.96M | 391.82M | -378.47M |
| Capital Expenditure | -271.00K | -294.00K | -1.02M | -1.24M | -2.46M | -1.93M | -1.55M |
| Free Cash Flow | -16.27M | -37.19M | -63.17M | -71.30M | -126.97M | -162.80M | 105.95M |
| Share Buybacks | - | - | - | - | - | 0 | 375.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -105.6% | - | -280.5% | - | -112,543.7% | -5,939.0% | 27.7% |
| Net Margin % | -123.4% | - | -292.3% | - | -101,319.2% | -5,277.5% | 35.7% |
| ROE % | 63.4% | -17.3% | -24.2% | -37.7% | -46.1% | -32.8% | 28.7% |
| ROCE % | -163.3% | -17.8% | -23.2% | -39.6% | -49.2% | -35.8% | 21.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 14.09% | 2.79M | $30.82M |
| 2 | Nantahala Capital Management, LLC | 7.11% | 1.41M | $15.56M |
| 3 | AQR Capital Management, LLC | 4.88% | 967.86K | $10.68M |
| 4 | Vanguard Capital Management LLC | 4.20% | 833.60K | $9.19M |
| 5 | Orbimed Advisors LLC. | 3.83% | 759.15K | $8.37M |
| 6 | Federated Hermes, Inc. | 3.53% | 700.43K | $7.73M |
| 7 | Vanguard Portfolio Management LLC | 3.29% | 652.63K | $7.20M |
| 8 | Mackenzie Financial Corporation | 3.17% | 628.44K | $6.93M |
| 9 | Madison Avenue Partners, LP | 3.16% | 626.58K | $6.91M |
| 10 | Qube Research & Technologies Ltd | 3.07% | 608.84K | $6.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KROS
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQZXk4OHgzM2J0QWxVMkFhQ1pQdGJUdHI0WDBxajhlbU01VTFwc05qbHh1MGdfcVFJeVpYQS01R3l3dGdpWWRMTkNLbkN4bXgzVDFHTlY3cGNaeTlFRlVsYTBHUG1oNUpZaFZpUGFhZWNFOVFNbjJpWWRLVmNlaTRjRnE1eC1jRXpnb20zak…
Empowered Funds LLC Makes New Investment in Keros Therapeutics, Inc. $KROS - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPOUd5MVJSU1gtb0NCUkRERkRDUnZ4ZndQdlNQcUFWTEYxV0prSTc1TE1UYVM4LTlKaEFDYUZWcXphcVllekxoY21DNmZESVk1eUk3TWZBMmlTNEJxN0dPRG5MZHVSS0pmSHViZVE5RHZtQ2NXbzMzMzh0dmVrT1V0U2VSZWJ1N2lac205MD…
Keros Therapeutics director Bienaime buys $10,270 of KROS stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPSE8zS0VrRnhGQmdSMW0wUkxTb29DcG9sQUh0cFVVcVU2Tjh2YlNtNVRpZHVkSzFGVzZNWU9sQVlsWnhBSm1JREJBTXVtcHp0RExWOUNQRGdBQ3Z2dktLLTRubjdUQTZTR1I2N0w0Vk54VGtmMHR5SXhjcFBpWWROWkxzamdPVVZybWM4ek…
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNM2lnQ3NpMnZncDFuRzBrMlhjUUZPTXdmNEdvMmxKbEpMV3I1VFNGMzRNNDNYcHlPXzgzWFZhd2RMNFRPRUlxeVhtZWtudXhpRk5iUnFJcmlQZmFWUUNKdFFlQURDWDVaUEtlbkpSS0VZbUgwR3lOTld4LWFaR09WSnR6VFB5OVJCY01BeG…
Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQVGR5MndQMW5lcEVxOXAxa3prZUFVRlpUVlhpLUVuMEhLUk1iUnFqYWZXcjVPUWxXYThpQktBSElMR2VHMWUzbWpWOFRxcHM5TUlLVHhYM3I2TzJmQTVvaU43Z1dtUFhMNkZrQjB0cHRHLXN2cEtyLW5aam1RVWROVDdFTGcxREhmMTQ0MF…
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - qz.com
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9ZZUtDY1hRdjl2eWtzcVJWcWtjNmZjVDJLc3FYbEhKcEFrS1BmX2xjSG5lVTVwN3N1MENKdFpNRHJBakpDcnRGRGFQY0dqZTRlTkEya1AtZ1psUnFqSUlVUFMzUlRueXl6TXFXUEphdERVUF9KLUNlTjFJdzNVZ2s?oc=5" target="_bla…
KROS — Frequently Asked Questions
What is the current share price of Keros Therapeutics, Inc. (KROS)?
As of 2026-09-07 16:24 PDT, Keros Therapeutics, Inc. (KROS) trades at $11.32 on NasdaqGM. Its 52-week range is $9.91 to $21.84.
What is the market capitalisation of KROS?
Keros Therapeutics, Inc. (KROS) has a market capitalisation of $224.44M on NasdaqGM.
What is the P/E ratio of KROS?
KROS trades at a trailing price-to-earnings (P/E) ratio of -3.52. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.77.
What is the return on equity (ROE) of KROS?
KROS has a return on equity (ROE) of -17.16%. Its return on capital employed (ROCE) is 21.27%.
Is KROS a good stock to buy?
This page provides a data-driven analysis of Keros Therapeutics, Inc. (KROS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.